Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 5Thoracic 2Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 385Myelodysplastic Syndromes 153Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 27Hematologic Neoplasms 20Myeloproliferative Disorders 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Anemia, Refractory, with Excess of Blasts 14Neoplasms 13Neoplasm, Residual 11Multiple Myeloma 11Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Lymphoma, Non-Hodgkin 10Leukemia, Myelomonocytic, Acute 10Primary Myelofibrosis 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic-Myeloproliferative Diseases 8Lymphoma 8Leukemia, Myeloid 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8Leukemia, Myelomonocytic, Juvenile 5Hodgkin Disease 5GATA2 Deficiency 5Lymphoma, Large B-Cell, Diffuse 4

Interventions

Filgrastim 4Cyclophosphamide 4Psychiatric Rehabilitation 3Palliative Care 3Busulfan 3aflibercept 2Vincristine 2Thalidomide 2Radiotherapy 2Paclitaxel 2Melphalan 2Leucovorin 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2Docetaxel 2Celecoxib 2Azacitidine 2Analgesia 2venetoclax 1trimetrexate glucuronate 1tazemetostat 1tanespimycin 1sargramostim 1romidepsin 1ripretinib 1pembrolizumab 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Azacitidine × Other hematologic neoplasm × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡